About this trial
CLYMAX is a two-phase observational study that assess multiple aspects of chemsex and young men who have sex with men (YMSM).
Phase I of the study (CLYMAX,IRB No. 0695/65) was a cross-sectional descriptive study using a mixed methods data collection (focusing on qualitative data collection) assessing multiple aspects of chemsex, including the patterns of chemsex use and the perspectives on factors influencing chemsex initiation/discontinuation, effects on physical health, mental health and social outcomes, and the necessary services for a comprehensive chemsex clinic among YMSM; and the acceptability and feasibility of developing a comprehensive chemsex clinic from the perspective of YMSM, their family members or peers, and clinic staff.
This phase II study (CLYMAX-2) will be a prospective cohort study using a quantitative data collection exploring the effectiveness of the implementation strategy of harm reduction models and consist of a larger number of YMSM, important baseline and follow-up information on multiple aspects of physical, psychological, and social harms.
Eligibility criteria
Qualifiers
Men who have sex with men
Aged 16-35 years
Current chemsex users (defined as last chemsex used within 3 months)
Able to read and communicate in Thai
Disqualifiers
None
Trial design
Treatments tested in this trial
- Group1
Treatment groups
Sponsors and collaborators
Institute of HIV Research and Innovation Foundation, Thailand
Lead sponsor
The US NIH through the International Epidemiology Databases to Evaluate AIDS (IeDEA) IeDEA Asia-Pacific
Collaborator
amfAR, The Foundation for AIDS Research
Collaborator